Natera (NTRA) traded higher Tuesday as the market digested a fresh legal win that improves the company’s expected economics around its molecular residual disease (MRD) intellectual property. In an April 6, 2026 decision from the U.S. District Court in Delaware, the judge ordered an ongoing 30% royalty to Natera on post-injunction revenues from infringing MRD-related product sales that fall within specific exceptions to the injunction, reinforcing the durability and monetization potential of Natera’s MRD patent estate. (investor.natera.com)

A court-set running royalty can translate into higher-margin revenue with minimal incremental operating expense, and it can also increase Natera’s leverage in any future settlement discussions involving MRD testing products. Investors are likely viewing the 30% rate as a stronger-than-typical signal of perceived patent strength and infringement economics, supporting the narrative that MRD remains a structurally attractive profit pool alongside Natera’s ongoing test-volume growth.

Key swing factors include how much infringing sales volume remains after the injunction, how broadly the royalty applies in practice under the ruling’s exceptions, and whether any post-trial motions or appeals materially alter timing or ultimate cash collection. The next meaningful catalyst will be any quantified disclosure around royalty impact (or updated legal commentary) that helps investors model the contribution to 2026 results. (investor.natera.com)